Rottlerin inhibits cell growth, induces apoptosis and cell cycle arrest, and inhibits cell invasion in human hepatocellular carcinoma

JICHAN SHI1, HONGYE NING1, GUIQING HE1, YITONG HUANG2, ZHENGXING WU1, LINGLING JIN1 and XIANGAO JIANG1

Departments of 1Infectious Disease and 2Gynecologic Oncology, Wenzhou Central Hospital, Wenzhou, Zhejiang 325000, P.R. China

Received January 6, 2017; Accepted August 1, 2017

DOI: 10.3892/mmr.2017.7924

Abstract. Rottlerin, a polyphenolic compound, has been demonstrated to exhibit antitumor activity in various types of human cancer. Several studies have revealed that rottlerin exerts its anticancer function through PKC-dependent and independent pathways. The transcriptional co-activator with PDZ-binding motif (TAZ) oncoprotein is an important molecule in regulation of the Hippo pathway in human cancer. The present study investigated whether rottlerin has a tumor suppressive role via inhibiting the expression of TAZ, using cell viability assay, apoptosis and cell cycle analyses, western blot analysis and Transwell invasion assay. The results demonstrated that rottlerin suppressed cell growth, triggered cell apoptosis and induced cell cycle arrest. In addition, rottlerin inhibited cell migration and invasion in hepatocellular carcinoma (HCC) cells. Mechanistically, the results demonstrated that rottlerin suppressed cell growth, triggered cell apoptosis and induced cell cycle arrest. In addition, rottlerin inhibited cell migration and invasion in hepatocellular carcinoma (HCC) cells. Taken together, these findings indicated that the inhibition of TAZ by rottlerin may be a novel strategy for treating HCC.

Introduction

Hepatocellular carcinoma (HCC) is a life-threatening type of cancer, which is one of the common tumors in humans. It was predicted that there were 39,230 new cases of HCC with an HCC-associated mortality rate of 27,170 in 2016 in the United States (1). In contrast to the decreasing trends for other major cancer types, the mortality rate for HCC has increased. In China, 466,100 new cases of HCC were predicted and 422,100 patients were predicted to succumb to HCC-associated mortality in 2015 (2). Although several treatments, including surgery, radiation and chemotherapy, have been used to treat patients with HCC, the survival rate has not improved significantly (3). Therefore, the identification of novel agents is essential to improve the treatment effects in patients with HCC.

Rottlerin, also known as mallotoxin, is isolated from Mallotus phillippinensis (4). It has been reported that rottlerin inhibits tumorigenesis through the regulation of several mechanisms involving cells, including cell survival, apoptosis, autophagy and invasion (4). Rottlerin was initially identified as a potential protein kinase C (PKC) inhibitor 20 years ago (5). Several studies have confirmed that rottlerin inhibits cell proliferation and induces cell cycle arrest via the inhibition of protein kinase in several types of tumor in humans (6,7). Subsequent studies have revealed that rottlerin exerts its tumor suppressor function via a PKC-independent pathway. For example, rottlerin was found to sensitize to tumor necrosis-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through uncoupling of the mitochondria independently of PKC (8). Similarly, rottlerin was found to sensitize TRAIL-induced apoptosis via the suppression of cell division cycle (Cdc)2, survivin and X-linked inhibitor of apoptosis (XIAP) in glioma cells (9). Rottlerin has also been shown to suppress nuclear factor-kB and cyclin D1 in breast cancer cells (10). Studies have also shown that rottlerin inhibits caspase-2, and induces autophagy and apoptotic cell death (11,12). These findings indicate that rottlerin may regulate multiple genes to inhibit tumorigenesis.

The oncoprotein transcriptional co-activator with PDZ-binding motif (TAZ) has been identified as a key driver in the Hippo pathway; the Hippo signaling pathway is an essential regulator of organ size during developmental growth (13). Two transcription factors in the Hippo pathway, Yes-associated protein (YAP) and TAZ, have shown to possess oncogenic functions. The overexpression of TAZ was found to be significantly associated with poor overall survival in HCC
and gastrointestinal cancer (14). The overexpression of TAZ is also associated with certain clinicopathologic characteristics, including tumor-node-metastasis stage, lymph node metastasis and tumor differentiation (14). Higher expression levels of TAZ have also been reported to indicate a poor prognosis in retinoblastoma (15). Therefore, TAZ offers potential as a therapeutic target in human cancer (16). The present study aimed to investigate whether rottlerin inhibits cell growth, migration and invasion, and whether it induces cell apoptosis and cell cycle arrest in HCC cells. In addition, the present study examined whether rottlerin affects the expression of TAZ in HCC cells. The results demonstrated that rottlerin suppressed cell growth, triggered cell apoptosis and induced cell cycle arrest. In addition, rottlerin inhibited cell migration and invasion of the HCC cells. Mechanistically, the results showed that rottlerin exerted its antitumor activity partly through the inhibition of TAZ. Taken together, these findings indicated that the inhibition of TAZ by rottlerin may be a useful approach for treating HCC.

Materials and methods

Cell culture and reagents. The human QGY-7703 cell line was purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences (Shanghai, China), and cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc.) and 1% penicillin-streptomycin in a 5% CO₂ atmosphere at 37°C. Anti-TAZ antibody (1:1,000, sc-17130) was purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Secondary antibodies (anti-mouse HRP-linked antibody, #7076, 1:4,000; anti-rabbit HRP-linked antibody, #7074, 1:4,000) were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA). Monoclonal anti-tubulin antibody (1:3,000, T-3526), rottlerin (CAS no. R5648; ≥85% rottlerin) and Cell Signaling Technology (Shanghai, China) using Lipofectamine 2000 according to the manufacturer’s protocol. HCC cells in serum-free medium containing rottlerin (1, 2 or 3 µM) were seeded onto inserts in the upper chamber (1x10⁴ cells/well) in a 24-well plate. The lower wells were filled with complete medium with the same concentration of rottlerin. Following incubation for 20 h in a humidified CO₂ incubator at 37°C, the cells in the upper chambers were removed using cotton buds. The cells on the lower surface of the chambers were stained with 4 µg/ml Calcein AM in PBS at 37°C for 1 h. Images of these fluorescently labeled invasive cells were captured under a fluorescent microscope. The invaded cells on the membrane were stained with Wright’s-Giemsa and images were captured (17).

Cell transfection. The cells were seeded into a 6-well plate and transfected with TAZ small interfering (si)RNA or control siRNA (A06001; Shanghai GenePharma Co., Ltd., Shanghai, China) using Lipofectamine 2000 according to the manufacturer's protocol. The TAZ siRNA sequences were as follows: Sense, 5'-GCAUCUUCAGUCAGUCUCUUTT-3' and antisense, 5'-AGAAACUGUCAAGAUGCTT-3'. Following transfection, the cells were subjected to the analyses described above.

Statistical analysis. All statistical analyses were performed using GraphPad Prism 5.0 (Graph Pad Software, Inc., La Jolla, CA, USA). Student’s t-test was performed to evaluate statistical significance. The results are presented as the mean ± standard deviation. P<0.05 was considered to indicate a statistically significant difference.
Results

Rottlerin inhibits cell proliferation. To determine whether rottlerin suppresses the proliferation of HCC cells, a CTG assay was performed to examine the viability of QGY-7703 cells treated with different concentrations of rottlerin for 48 and 72 h. The results showed that rottlerin significantly inhibited cell proliferation in the two HCC cell lines (Fig. 1). The half maximal inhibitory concentration (IC50), which is the concentration leading to 50% cell growth inhibition, was ~1 µM at 72 h for the QGY-7703 cells. These results suggested that the QGY-7703 cells were sensitive to rottlerin treatment. Therefore, a 1 µM concentration of rottlerin was used for QGY-7703 cells in the subsequent experiments.

Rottlerin induces apoptosis. The present study also aimed to determine whether rottlerin enhances the apoptosis of HCC cells. A PI-FITC-Annexin assay was performed to measure the rates of apoptotic death of HCC cells following treatment with rottlerin for 48 h. It was found that rottlerin triggered cell apoptosis in the HCC cells (Fig. 2). Specifically, cell apoptosis was increased from 7.0% in the control group to 18.5 and 26.96% in the 1 and 2 µM rottlerin-treated QGY-7703 cell groups, respectively (Fig. 2). These findings indicated that rottlerin stimulated the apoptosis of HCC cells.

Rottlerin induces cell cycle arrest. To further define the role of rottlerin in cell growth inhibition, the present study measured cell cycle in the HCC cells following rottlerin treatment. Cell cycle analysis using PI staining and flow cytometry was performed in the HCC cells. The results revealed that rottlerin induced G0/G1 arrest in the QGY-7703 cells (Fig. 3). Treatment with 1 µM rottlerin led to an increase in the percentage of G0/G1 cells from 57.85 to 73.88% in the QGY-7703 cells. These
results demonstrated that rottlerin induced cell cycle G0/G1 arrest.

**Rottlerin inhibits cell invasion.** Rottlerin has been reported to inhibit cell invasion in pancreatic cancer cells (17). To analyze whether rottlerin can inhibit the cell motility of HCC cells, the present study performed an invasion assay using Matrigel-coated membranes. The results showed that rottlerin treatment led to decreased penetration of the HCC cells through the Matrigel-coated membrane, compared with that of the control cells (Fig. 4). In addition, the results showed that the numbers of fluorescently-labeled invasive cells were significantly reduced by rottlerin treatment in the HCC cells (Fig. 5). These results suggested that rottlerin inhibited cell invasion of the HCC cells.

**Rottlerin decreases the expression of TAZ.** It has been shown that TAZ exerts oncogenic functions in tumorigenesis (19). To determine whether rottlerin mediates antitumor activity via regulating the expression of TAZ in HCC cells, the present study measured the expression of TAZ in HCC cells treated with rottlerin using western blot analysis. The results from the western blot analysis showed that rottlerin significantly downregulated the expression of TAZ in the QGY-7703 cells (Fig. 6). This finding indicated that rottlerin exhibited anticancer activity at least partly due to the inhibition of TAZ in HCC cells.

**Down-regulation of TAZ enhances rottlerin-induced inhibition of cell growth.** To further confirm the role of TAZ in rottlerin-induced cell growth inhibition, the HCC cells were transfected with TAZ siRNA. It was found that TAZ siRNA decreased the expression of TAZ in QGY-7703 cells (Fig. 7A). The results of the CTG assay showed that the depletion of TAZ inhibited cell growth (Fig. 7B). It was also observed that the downregulation of TAZ inhibited cell invasion (Fig. 7C). Of note, cell growth was significantly inhibited by rottlerin combined with TAZ siRNA transfection (Fig. 7D). These results suggested that rottlerin suppressed cell growth partly due to the inhibition of TAZ in HCC cells.

**Discussion**

There is increasing evidence supporting the potential antitumor activity of rottlerin in human cancer. For example, rottlerin has been shown to induce Wnt co-receptor LRP6 degradation, and inhibit Wnt/β-catenin and mammalian target of rapamycin (mTOR) C1 signaling in prostate and breast cancer cells (20). Kumar et al (21) reported that rottlerin induced autophagy and apoptosis via regulation of the phosphoinositide 3-kinase (PI3K)/Akt/mTOR signaling pathway in prostate and pancreatic cancer stem cells (22). Lim et al (23) found that rottlerin induced apoptosis via regulating extracellular signal regulated kinase (ERK) and p38 mitogen-activated

---

![Figure 4](image1.png)  
**Figure 4.** Rottlerin inhibits QGY-7703 cell invasion. (A) Inhibitory effect of rottlerin on hepatocellular carcinoma cell invasion was detected using a Transwell chamber assay. The invaded cells on the membrane were stained with Wright's-Giemsa and images were captured (magnification, x40). (B) Quantification of the results. *P<0.05 and **P<0.01, vs. control.

![Figure 5](image2.png)  
**Figure 5.** Rottlerin inhibits QGY-7703 cell invasion. (A) Inhibitory effect of rottlerin on cell invasion was measured using a Transwell chamber assay. The hepatocellular carcinoma cells in serum-free medium containing rottlerin were seeded into the upper chamber of inserts in a 24-well plate. Lower wells were filled with complete medium containing the same concentration of rottlerin. After 20 h, the cells on the lower surface of the chambers were stained with 4 µg/ml Calcein AM in PBS buffer at 37°C for 1 h. Images of the fluorescently-labeled invasive cells were captured (magnification, x10) under a fluorescent microscope. (B) Relative number of invaded cells. *P<0.05, vs. control.

![Figure 6](image3.png)  
**Figure 6.** Rottlerin downregulates the protein expression levels of TAZ. (A) Expression of TAZ was determined using western blot analysis in QGY-7703 cells following rottlerin treatment. (B) Semi-quantification of relative TAZ expression. *P<0.05 and **P<0.01, vs. control. TAZ, transcriptional co-activator with PDZ-binding motif.
cell growth and invasion. TAZ has also been shown to promote EMT and support pancreatic cancer progression (27). In accordance, the knockdown of TAZ modifies cell sensitivity to EGFR inhibitors in triple-negative breast cancer cells (28). TAZ and YAP regulate pancreatic cancer initiation in mice via the direct upregulation of JAK-STAT3 signaling (29). Further investigation is required to examine the mechanism underlying TAZ-induced ovarian tumorigenesis.

As TAZ is a key oncoprotein, it is important to identify its inhibitors. Several groups have identified multiple inhibitors of TAZ. It has been reported that statins attenuate cell proliferative ability and induce apoptosis through TAZ in HCC cells (30), and statins have been shown to improve the prognosis of patients with HCC (30). Curcumin has been reported to downregulate the expression of TAZ in pancreatic cancer cells (31). In accordance, curcumin promotes the degradation of Krueppel-like factor 5 via the downregulation of YAP/TAZ in bladder cancer cells (32). Dasatinib, statins and pazopanib have been shown to inhibit the nuclear localization of TAZ via inducing the phosphorylation of TAZ (33). Pazopanib has also been shown to induce the proteasomal degradation of YAP/TAZ (33). The present study identified rottlerin as a potential inhibitor of TAZ in HCC. The present study confirmed that the rottlerin-induced inhibition of cell proliferation, induction of cell apoptosis and cell cycle arrest, and suppression of cell invasion and migration in HCC occurred partly through the downregulation of TAZ. Therefore, the inhibition of TAZ by rottlerin may be an effective approach for the treatment of HCC. Further investigations are required to investigate the functions of rottlerin in additional HCC cell lines and in HCC in vivo models.

References


